No abstract available
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anticoagulants / adverse effects
-
Anticoagulants / therapeutic use
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Benzimidazoles / adverse effects
-
Benzimidazoles / therapeutic use
-
Carcinoma, Neuroendocrine
-
Clinical Trials as Topic
-
Dabigatran
-
Drug Approval*
-
Efficiency, Organizational*
-
Fingolimod Hydrochloride
-
Humans
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use
-
Multiple Sclerosis / drug therapy
-
Patient Safety*
-
Piperidines / adverse effects
-
Piperidines / therapeutic use
-
Propylene Glycols / adverse effects
-
Propylene Glycols / therapeutic use
-
Quinazolines / adverse effects
-
Quinazolines / therapeutic use
-
Risk
-
Sphingosine / adverse effects
-
Sphingosine / analogs & derivatives
-
Sphingosine / therapeutic use
-
Stroke / prevention & control
-
Thyroid Neoplasms / drug therapy
-
Time Factors
-
United States
-
United States Food and Drug Administration*
-
beta-Alanine / adverse effects
-
beta-Alanine / analogs & derivatives
-
beta-Alanine / therapeutic use
Substances
-
Anticoagulants
-
Antineoplastic Agents
-
Benzimidazoles
-
Immunosuppressive Agents
-
Piperidines
-
Propylene Glycols
-
Quinazolines
-
beta-Alanine
-
Fingolimod Hydrochloride
-
Dabigatran
-
Sphingosine
-
vandetanib
Supplementary concepts
-
Thyroid cancer, medullary